{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:58:38Z","timestamp":1793048318758,"version":"4.5.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by dysregulated differentiation and uncontrolled proliferation of myeloid precursor cells. AML is the second most common type of leukemia after acute lymphoblastic leukemia, yet it has the lower survival rates, with only approximately 30% of adult patients surviving five years post-diagnosis. Standard treatment regimens typically include intensive chemotherapy, advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) have significantly improved outcomes in the treatment of AML. Advances in molecular profiling technologies have significantly enhanced our understanding of the genetic and epigenetic alterations that drive AML, revealing numerous novel therapeutic targets. Consequently, targeted molecular therapies and epigenetic treatments are becoming increasingly important. Moreover, immunotherapy represents a promising therapeutic strategy that has demonstrated considerable potential in the context of AML. This review summarizes new strategies and emerging therapeutic targets in AML, with a particular focus on recent advancements in immunotherapy. It also explores the feasibility of integrating these therapeutic approaches into current treatment paradigms and their potential impact on future clinical practices.<\/jats:p>","DOI":"10.1186\/s40364-025-00839-2","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:01:10Z","timestamp":1760450470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions"],"prefix":"10.1186","volume":"13","author":[{"given":"Linyu","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"10393","key":"839_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet (London England). 2023;401(10393):2073\u201386.","journal-title":"Lancet (London England)"},{"key":"839_CR2","doi-asserted-by":"crossref","unstructured":"Shimony S, Stahl M, Stone RM, Acute Myeloid L. 2025 update on diagnosis, Risk-Stratification, and management. American journal of hematology. 2025.","DOI":"10.1002\/ajh.27625"},{"issue":"1","key":"839_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. Cancer J Clin. 2025;75(1):46\u201367.","journal-title":"Cancer J Clin"},{"issue":"12","key":"839_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627\u201335.","journal-title":"Blood"},{"issue":"1","key":"839_CR5","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27\u201342.","journal-title":"Nat Cancer"},{"issue":"7714","key":"839_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400\u20134.","journal-title":"Nature"},{"issue":"10147","key":"839_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet (London England). 2018;392(10147):593\u2013606.","journal-title":"Lancet (London England)"},{"issue":"10","key":"839_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia: A review. JAMA Oncol. 2024;10(10):1417\u201325.","journal-title":"JAMA Oncol"},{"issue":"13","key":"839_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249\u201359.","journal-title":"N Engl J Med"},{"key":"839_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers13225608","volume":"13","author":"S Garciaz","year":"2021","unstructured":"Garciaz S, Saillard C, Hicheri Y, Hospital MA, Vey N. Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance. Cancers. 2021;13:22.","journal-title":"Cancers"},{"issue":"22","key":"839_CR11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"4","key":"839_CR12","first-page":"485","volume":"57","author":"JW Yates","year":"1973","unstructured":"Yates JW, Wallace HJ Jr., Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and Daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485\u20138.","journal-title":"Cancer Chemother Rep"},{"issue":"13","key":"839_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose Daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235\u201348.","journal-title":"N Engl J Med"},{"issue":"18","key":"839_CR14","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood. 2009;113(18):4179\u201387.","journal-title":"Blood"},{"key":"839_CR15","doi-asserted-by":"crossref","unstructured":"Okoniewski M, Gonzalez Lugo J, Lin TL. Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2025;45(3):e473646.","DOI":"10.1200\/EDBK-25-473646"},{"issue":"8","key":"839_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93(8):1074\u201381.","journal-title":"Am J Hematol"},{"key":"839_CR17","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Collette Y, Vey N. Venetoclax resistance in acute myeloid leukemia. Cancers. 2024;16(6).","DOI":"10.3390\/cancers16061091"},{"issue":"5","key":"839_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Konopleva M. AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci. 2024;45(5):430\u201348.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"839_CR19","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, et al. Venetoclax plus 3\u2009+\u20097 Daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9(6):e415\u201324.","journal-title":"Lancet Haematol"},{"issue":"17","key":"839_CR20","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.2024026700","volume":"145","author":"I Mantzaris","year":"2025","unstructured":"Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K, et al. Venetoclax plus Daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study. Blood. 2025;145(17):1870\u20135.","journal-title":"Blood"},{"issue":"23","key":"839_CR21","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1158\/1078-0432.CCR-23-0917","volume":"29","author":"LN Harris","year":"2023","unstructured":"Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, et al. The new NCI precision medicine trials. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29(23):4728\u201332.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"839_CR22","doi-asserted-by":"publisher","first-page":"659595","DOI":"10.3389\/fimmu.2021.659595","volume":"12","author":"J Loke","year":"2021","unstructured":"Loke J, Buka R, Craddock C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?? Front Immunol. 2021;12:659595.","journal-title":"Front Immunol"},{"key":"839_CR23","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Biology of blood and marrow transplantation: journal of the American society for blood and marrow transplantation. 2015;21(3):389\u2013e4011.","DOI":"10.1016\/j.bbmt.2014.12.035"},{"issue":"1","key":"839_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41408-025-01223-x","volume":"15","author":"C Jim\u00e9nez-Vicente","year":"2025","unstructured":"Jim\u00e9nez-Vicente C, Esteve J, Baile-Gonz\u00e1lez M, P\u00e9rez-L\u00f3pez E, Martin Calvo C, Aparicio C, et al. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish group for hematopoietic cell transplantation (GETH-TC). Blood Cancer J. 2025;15(1):42.","journal-title":"Blood Cancer J"},{"key":"839_CR25","doi-asserted-by":"crossref","unstructured":"de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM et al. Proceedings from the National Cancer Institute\u2019s Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2014;20(1):4\u201313.","DOI":"10.1016\/j.bbmt.2013.08.012"},{"key":"839_CR26","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"7","key":"839_CR27","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3324\/haematol.2022.281877","volume":"108","author":"Y Yerushalmi","year":"2023","unstructured":"Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, et al. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndromes after a first transplantation. Haematologica. 2023;108(7):1782\u201392.","journal-title":"Haematologica"},{"issue":"1","key":"839_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.blre.2012.11.002","volume":"27","author":"YJ Chang","year":"2013","unstructured":"Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev. 2013;27(1):55\u201362.","journal-title":"Blood Rev"},{"issue":"31","key":"839_CR29","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornh\u00e4user M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncology: Official J Am Soc Clin Oncol. 2007;25(31):4938\u201345.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"11","key":"839_CR30","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.3324\/haematol.2022.282570","volume":"108","author":"T Schroeder","year":"2023","unstructured":"Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch JH, et al. Azacitidine, Lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica. 2023;108(11):3001\u201310.","journal-title":"Haematologica"},{"issue":"10","key":"839_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-020-00431-7","volume":"17","author":"D Romero","year":"2020","unstructured":"Romero D. Sorafenib prevents AML relapse after allo-HSCT. Nat Reviews Clin Oncol. 2020;17(10):591.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7954","key":"839_CR32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The Menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134.","journal-title":"Nature"},{"issue":"1","key":"839_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, et al. Small molecules Co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models. Cell. 2018;175(1):171\u2013e8525.","journal-title":"Cell"},{"issue":"19","key":"839_CR34","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1056\/NEJMcibr1811318","volume":"379","author":"BL Ebert","year":"2018","unstructured":"Ebert BL, Kr\u00f6nke J. Inhibition of casein kinase 1 alpha in acute myeloid leukemia. N Engl J Med. 2018;379(19):1873\u20134.","journal-title":"N Engl J Med"},{"issue":"11","key":"839_CR35","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1021\/jacsau.4c00762","volume":"4","author":"L Huang","year":"2024","unstructured":"Huang L, Chen L, Chen L, Peng B, Zhou L, Sun Y, et al. Development of oral, potent, and selective CK1\u03b1 degraders for AML therapy. JACS Au. 2024;4(11):4423\u201334.","journal-title":"JACS Au"},{"issue":"1","key":"839_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-025-01724-z","volume":"18","author":"BJ Ball","year":"2025","unstructured":"Ball BJ, Xiao W, Borthakur G, Nguyen LXT, Valerio M, Venkatachalam A, et al. Phase I first-in-human dose escalation study of the oral casein kinase 1\u03b1 and Cyclin dependent kinase 7\/9 inhibitor BTX A51 in advanced MDS and AML. J Hematol Oncol. 2025;18(1):73.","journal-title":"J Hematol Oncol"},{"issue":"23","key":"839_CR37","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"12","key":"839_CR38","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, G\u00f6nen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079\u201389.","journal-title":"N Engl J Med"},{"issue":"7728","key":"839_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"4","key":"839_CR40","doi-asserted-by":"publisher","first-page":"e70151","DOI":"10.1002\/mco2.70151","volume":"6","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liu L, Qin J, Ni X, Jin J. Stable expressed DNMT3A mutants predict a poor prognosis in acute myeloid leukemia patients without receiving hematopoietic stem cell transplantation. MedComm. 2025;6(4):e70151.","journal-title":"MedComm"},{"key":"839_CR41","doi-asserted-by":"publisher","first-page":"108169","DOI":"10.1016\/j.bioorg.2025.108169","volume":"156","author":"T Das","year":"2025","unstructured":"Das T, Bhar S, Ghosh D, Kabi B, Kar K, Chandra A. A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors. Bioorg Chem. 2025;156:108169.","journal-title":"Bioorg Chem"},{"key":"839_CR42","doi-asserted-by":"publisher","first-page":"116847","DOI":"10.1016\/j.ejmech.2024.116847","volume":"279","author":"Y Chang","year":"2024","unstructured":"Chang Y, Li X, Zhou Y, Yang X, Zhao W, Fang H, et al. Simultaneous Inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia. Eur J Med Chem. 2024;279:116847.","journal-title":"Eur J Med Chem"},{"key":"839_CR43","doi-asserted-by":"publisher","first-page":"111583","DOI":"10.1016\/j.cellsig.2024.111583","volume":"127","author":"R Bian","year":"2025","unstructured":"Bian R, Shang Y, Xu N, Liu B, Ma Y, Li H, et al. HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism. Cell Signal. 2025;127:111583.","journal-title":"Cell Signal"},{"key":"839_CR44","doi-asserted-by":"publisher","first-page":"1287444","DOI":"10.3389\/fonc.2023.1287444","volume":"13","author":"BC Valdez","year":"2023","unstructured":"Valdez BC, Yuan B, Murray D, Ramdial JL, Nieto Y, Popat U, et al. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, Vorinostat and Olaparib in AML cells. Front Oncol. 2023;13:1287444.","journal-title":"Front Oncol"},{"key":"839_CR45","doi-asserted-by":"crossref","unstructured":"Pal D, Raj K, Nandi SS, Sinha S, Mishra A, Mondal A et al. Potential of synthetic and natural compounds as novel histone deacetylase inhibitors for the treatment of hematological malignancies. Cancers. 2023;15(10).","DOI":"10.3390\/cancers15102808"},{"issue":"10","key":"839_CR46","doi-asserted-by":"publisher","first-page":"e29812","DOI":"10.1002\/pbc.29812","volume":"69","author":"ES Schafer","year":"2022","unstructured":"Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, et al. Real-world experience in treating pediatric relapsed\/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022;69(10):e29812.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"839_CR47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jtct.2022.05.021","volume":"28","author":"G Alatrash","year":"2022","unstructured":"Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, et al. Vorinostat combined with busulfan, fludarabine, and Clofarabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute leukemia: Long-Term study outcomes. Transplantation Cell Therapy. 2022;28(8):501.e1-.e7.","journal-title":"Transplantation Cell Therapy"},{"issue":"1","key":"839_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","volume":"38","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, et al. A randomized phase III study of standard versus high-dose cytarabine with or without Vorinostat for AML. Leukemia. 2024;38(1):58\u201366.","journal-title":"Leukemia"},{"issue":"2","key":"839_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41573-024-01080-6","volume":"24","author":"MM Zhou","year":"2025","unstructured":"Zhou MM, Cole PA. Targeting lysine acetylation readers and writers. Nat Rev Drug Discovery. 2025;24(2):112\u201333.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"839_CR50","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2159-8290.CD-20-1459","volume":"12","author":"F Yan","year":"2022","unstructured":"Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, et al. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic Gene-Expression programs. Cancer Discov. 2022;12(3):792\u2013811.","journal-title":"Cancer Discov"},{"key":"839_CR51","doi-asserted-by":"crossref","unstructured":"Michmerhuizen NL, Heikamp EB, Iacobucci I, Umeda M, Arthur B, Mishra V et al. KAT6A and KAT7 histone acetyltransferase complexes are molecular dependencies and therapeutic targets in NUP98-Rearranged acute myeloid leukemia. Cancer Discov. 2025.","DOI":"10.1158\/2159-8290.30284419"},{"issue":"1","key":"839_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10142-025-01563-8","volume":"25","author":"P Goleij","year":"2025","unstructured":"Goleij P, Heidari MM, Tabari MAK, Hadipour M, Rezaee A, Javan A, et al. Polycomb repressive complex 2 (PRC2) pathway\u2019s role in cancer cell plasticity and drug resistance. Funct Integr Genom. 2025;25(1):53.","journal-title":"Funct Integr Genom"},{"issue":"1","key":"839_CR53","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12864-025-11415-1","volume":"26","author":"E Georges","year":"2025","unstructured":"Georges E, Ho W, Iturritza MU, Eory L, Malysz K, Sobhiafshar U, et al. Transcriptomic characterisation of acute myeloid leukemia cell lines bearing the same t(9;11) driver mutation reveals different molecular signatures. BMC Genomics. 2025;26(1):300.","journal-title":"BMC Genomics"},{"key":"839_CR54","doi-asserted-by":"publisher","first-page":"107964","DOI":"10.1016\/j.bioorg.2024.107964","volume":"153","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yang M, Liu Q, Xue X, Tian S, Hu X, et al. Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorg Chem. 2024;153:107964.","journal-title":"Bioorg Chem"},{"key":"839_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","volume":"413","author":"S Wen","year":"2018","unstructured":"Wen S, Wang J, Liu P, Li Y, Lu W, Hu Y, et al. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo. Cancer Lett. 2018;413:35\u201345.","journal-title":"Cancer Lett"},{"key":"839_CR56","doi-asserted-by":"publisher","first-page":"107771","DOI":"10.1016\/j.bioorg.2024.107771","volume":"153","author":"B Sethy","year":"2024","unstructured":"Sethy B, Yu ZY, Narwanti I, Upadhyay R, Lai MJ, Lee SB, et al. Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents. Bioorg Chem. 2024;153:107771.","journal-title":"Bioorg Chem"},{"issue":"13","key":"839_CR57","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/bloodadvances.2020001922","volume":"4","author":"MC Kingsley","year":"2020","unstructured":"Kingsley MC, Xie HM, Chen BR, Riedel SS, Pastuer T, Bollig MK, et al. Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML. Blood Adv. 2020;4(13):3109\u201322.","journal-title":"Blood Adv"},{"issue":"19","key":"839_CR58","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41388-024-03006-3","volume":"43","author":"T Guo","year":"2024","unstructured":"Guo T, Wang Y, Sun X, Hou S, Lan Y, Yuan S, et al. Loss of RNA-binding protein CELF2 promotes acute leukemia development via FAT10-mTORC1. Oncogene. 2024;43(19):1476\u201387.","journal-title":"Oncogene"},{"key":"839_CR59","first-page":"1300","volume-title":"Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine","author":"S Ito","year":"2011","unstructured":"Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Volume 333. New York, NY: Science. 2011;1300\u20133. 6047."},{"issue":"6047","key":"839_CR60","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1126\/science.1210944","volume":"333","author":"YF He","year":"2011","unstructured":"He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Sci (New York NY). 2011;333(6047):1303\u20137.","journal-title":"Sci (New York NY)"},{"issue":"6","key":"839_CR61","doi-asserted-by":"publisher","first-page":"e70792","DOI":"10.1002\/cam4.70792","volume":"14","author":"ZL Hawking","year":"2025","unstructured":"Hawking ZL, Allan JM. Landscape of TET2 mutations: from hematological malignancies to solid tumors. Cancer Med. 2025;14(6):e70792.","journal-title":"Cancer Med"},{"key":"839_CR62","doi-asserted-by":"crossref","unstructured":"Zhang P, Whipp EC, Skuli SJ, Gharghabi M, Saygin C, Sher SA et al. TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and Establish an immunosuppressive environment. J Clin Investig. 2025.","DOI":"10.1172\/JCI184021"},{"key":"839_CR63","doi-asserted-by":"crossref","unstructured":"Chatzikalil E, Arvanitakis K, Filippatos F, Diamantopoulos PT, Koufakis T, Solomou EE. Diagnostic and therapeutic implications of the sumoylation pathway in acute myeloid leukemia. Cancers. 2025;17(4).","DOI":"10.3390\/cancers17040631"},{"issue":"9","key":"839_CR64","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ajh.27385","volume":"99","author":"K Bauer","year":"2024","unstructured":"Bauer K, Hauswirth A, Gleixner KV, Greiner G, Thaler J, Bettelheim P, et al. BRD4 degraders May effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL. Am J Hematol. 2024;99(9):1721\u201331.","journal-title":"Am J Hematol"},{"key":"839_CR65","doi-asserted-by":"publisher","first-page":"117381","DOI":"10.1016\/j.ejmech.2025.117381","volume":"288","author":"Y Xu","year":"2025","unstructured":"Xu Y, Yang H, Li Y, Qi Y, Zhao F, Hong Y, et al. Discovery of highly potent dual GSPT1\/BRD4 degraders with anti-AML activity. Eur J Med Chem. 2025;288:117381.","journal-title":"Eur J Med Chem"},{"key":"839_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","volume":"103","author":"R Austin","year":"2016","unstructured":"Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol\/Hematol. 2016;103:62\u201377.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"839_CR67","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41590-022-01198-y","volume":"23","author":"Z Li","year":"2022","unstructured":"Li Z, Ma R, Ma S, Tian L, Lu T, Zhang J, et al. ILC1s control leukemia stem cell fate and limit development of AML. Nat Immunol. 2022;23(5):718\u201330.","journal-title":"Nat Immunol"},{"issue":"6","key":"839_CR68","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, R\u00f6llig C, Thiede C, Bornh\u00e4user M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218.","journal-title":"Blood Cancer J"},{"key":"839_CR69","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"839_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28(4):143\u201353.","journal-title":"Blood Rev"},{"issue":"19","key":"839_CR71","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1002\/cam4.3360","volume":"9","author":"SY Hyun","year":"2020","unstructured":"Hyun SY, Na EJ, Jang JE, Chung H, Kim SJ, Kim JS, et al. Immunosuppressive role of CD11b(+) CD33(+) HLA-DR(-) myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia. Cancer Med. 2020;9(19):7007\u201317.","journal-title":"Cancer Med"},{"issue":"12","key":"839_CR72","first-page":"1261","volume":"86","author":"L Mu\u00f1oz","year":"2001","unstructured":"Mu\u00f1oz L, Nomded\u00e9u JF, L\u00f3pez O, Carnicer MJ, Bellido M, Avent\u00edn A, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86(12):1261\u20139.","journal-title":"Haematologica"},{"issue":"12","key":"839_CR73","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34\u2009+\u2009CD38low\/-CD123\u2009+\u2009blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupe Ouest-Est des leucemies Aigues et maladies du sang (GOELAMS) study. Haematologica. 2011;96(12):1792\u20138.","journal-title":"Haematologica"},{"issue":"1","key":"839_CR74","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bjh.16307","volume":"188","author":"G Jiang","year":"2020","unstructured":"Jiang G, Atenafu EG, Capo-Chichi JM, Minden MD, Chang H. Prognostic relevance of CD123 expression in adult AML with normal karyotype. Br J Haematol. 2020;188(1):181\u20134.","journal-title":"Br J Haematol"},{"issue":"14","key":"839_CR75","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","volume":"120","author":"JA Yin","year":"2012","unstructured":"Yin JA, O\u2019Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the united Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826\u201335.","journal-title":"Blood"},{"issue":"24","key":"839_CR76","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Mr\u00f3zek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study. J Clin Oncology: Official J Am Soc Clin Oncol. 2005;23(24):5705\u201317.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"18","key":"839_CR77","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","volume":"22","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Benner A, Krauter J, B\u00fcchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup. J Clin Oncology: Official J Am Soc Clin Oncol. 2004;22(18):3741\u201350.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"2","key":"839_CR78","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/blood.V80.2.470.470","volume":"80","author":"K Kita","year":"1992","unstructured":"Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80(2):470\u20137.","journal-title":"Blood"},{"issue":"22","key":"839_CR79","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443\u201350.","journal-title":"Cancer Res"},{"key":"839_CR80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26\u201333.","journal-title":"Blood Rev"},{"key":"839_CR81","doi-asserted-by":"crossref","unstructured":"Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK et al. Development of A chimeric antigen receptor targeting C-Type Lectin-Like Molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017;18(11).","DOI":"10.3390\/ijms18112259"},{"key":"839_CR82","doi-asserted-by":"crossref","unstructured":"Liu HG, Lv L, Shen H. Intratumoral heterogeneity of CD44v6 in rectal cancer. Clinical & translational oncology: official publication of the federation of Spanish oncology societies and of the National cancer Institute of Mexico. 2017;19(4):425\u201331.","DOI":"10.1007\/s12094-016-1542-9"},{"key":"839_CR83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fcell.2018.00097","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhao K, Hackert T, Z\u00f6ller M. CD44\/CD44v6 a reliable companion in Cancer-Initiating cell maintenance and tumor progression. Front Cell Dev Biology. 2018;6:97.","journal-title":"Front Cell Dev Biology"},{"issue":"20","key":"839_CR84","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"M Casucci","year":"2013","unstructured":"Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461\u201372.","journal-title":"Blood"},{"issue":"9","key":"839_CR85","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1182\/blood.V91.9.3401","volume":"91","author":"S Legras","year":"1998","unstructured":"Legras S, G\u00fcnthert U, Stauder R, Curt F, Oliferenko S, Kluin-Nelemans HC, et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood. 1998;91(9):3401\u201313.","journal-title":"Blood"},{"issue":"4","key":"839_CR86","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318\u201330.","journal-title":"Blood"},{"issue":"1","key":"839_CR87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint Blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12(1):59.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"839_CR88","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14348\/molcells.2022.2056","volume":"45","author":"GR Kim","year":"2022","unstructured":"Kim GR, Choi JM. Current Understanding of cytotoxic T lymphocyte Antigen-4 (CTLA-4) signaling in T-Cell biology and disease therapy. Mol Cells. 2022;45(8):513\u201321.","journal-title":"Mol Cells"},{"key":"839_CR89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S500723","volume":"14","author":"C Chen","year":"2025","unstructured":"Chen C, Qiu K, Chen J, Wang S, Zhang Y, Wang C, et al. Increased Co-Expression of PD-L1 and CTLA-4 predicts poor overall survival in patients with acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. ImmunoTargets Therapy. 2025;14:25\u201333.","journal-title":"ImmunoTargets Therapy"},{"issue":"3","key":"839_CR90","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting Immunomodulatory checkpoints for cancer therapy. Cancer Biology Med. 2023;20(3):181\u201395.","journal-title":"Cancer Biology Med"},{"key":"839_CR91","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"FM Schnorfeil","year":"2015","unstructured":"Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"839_CR92","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1111\/cas.15042","volume":"112","author":"Y Kikushige","year":"2021","unstructured":"Kikushige Y. TIM-3 in normal and malignant hematopoiesis: structure, function, and signaling pathways. Cancer Sci. 2021;112(9):3419\u201326.","journal-title":"Cancer Sci"},{"issue":"27","key":"839_CR93","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA. 2013;110(27):11103\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"839_CR94","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2009.07.005","volume":"138","author":"DS Ritchie","year":"2009","unstructured":"Ritchie DS, Smyth MJ. A new therapeutic target for leukemia comes to the surface. Cell. 2009;138(2):226\u20138.","journal-title":"Cell"},{"issue":"6","key":"839_CR95","doi-asserted-by":"publisher","first-page":"114260","DOI":"10.1016\/j.celrep.2024.114260","volume":"43","author":"ME Bordeleau","year":"2024","unstructured":"Bordeleau ME, Audemard \u00c9, M\u00e9tois A, Theret L, Lisi V, Farah A, et al. Immunotherapeutic targeting of surfaceome heterogeneity in AML. Cell Rep. 2024;43(6):114260.","journal-title":"Cell Rep"},{"issue":"3","key":"839_CR96","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1607","volume":"28","author":"Y Saito","year":"2010","unstructured":"Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010;28(3):275\u201380.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"839_CR97","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","volume":"34","author":"AL Boyd","year":"2018","unstructured":"Boyd AL, Aslostovar L, Reid J, Ye W, Tanasijevic B, Porras DP, et al. Identification of Chemotherapy-Induced Leukemic-Regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell. 2018;34(3):483\u2013e985.","journal-title":"Cancer Cell"},{"key":"839_CR98","doi-asserted-by":"crossref","unstructured":"Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Investig. 2022;132(21).","DOI":"10.1172\/JCI159579"},{"issue":"21","key":"839_CR99","doi-asserted-by":"publisher","first-page":"e39731","DOI":"10.1016\/j.heliyon.2024.e39731","volume":"10","author":"CY Wang","year":"2024","unstructured":"Wang CY, Lin SC, Chang KJ, Cheong HP, Wu SR, Lee CH, et al. Immunoediting in acute myeloid leukemia: reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis. Heliyon. 2024;10(21):e39731.","journal-title":"Heliyon"},{"issue":"1","key":"839_CR100","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41467-023-41994-0","volume":"14","author":"H Mumme","year":"2023","unstructured":"Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Perumalla P, et al. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat Commun. 2023;14(1):6209.","journal-title":"Nat Commun"},{"issue":"1","key":"839_CR101","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/gene.2014.58","volume":"16","author":"A Baraga\u00f1o Raneros","year":"2015","unstructured":"Baraga\u00f1o Raneros A, Mart\u00edn-Palanco V, Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015;16(1):71\u201382.","journal-title":"Genes Immun"},{"issue":"8","key":"839_CR102","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-011-1050-2","volume":"60","author":"B Sanchez-Correa","year":"2011","unstructured":"Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunotherapy: CII. 2011;60(8):1195\u2013205.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"issue":"5","key":"839_CR103","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/blood.V96.5.1961","volume":"96","author":"UH Mellqvist","year":"2000","unstructured":"Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by Histamine. Blood. 2000;96(5):1961\u20138.","journal-title":"Blood"},{"issue":"2","key":"839_CR104","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1042\/CS20191170","volume":"134","author":"Z Wang","year":"2020","unstructured":"Wang Z, Xiao Y, Guan W, Wang M, Chen J, Zhang L, et al. Acute myeloid leukemia immune escape by epigenetic CD48 Silencing. Clin Sci (London England: 1979). 2020;134(2):261\u201371.","journal-title":"Clin Sci (London England: 1979)"},{"issue":"4","key":"839_CR105","first-page":"1107","volume":"109","author":"Y Kaito","year":"2024","unstructured":"Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, et al. Immune checkpoint molecule DNAM-1\/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia. Haematologica. 2024;109(4):1107\u201320.","journal-title":"Haematologica"},{"issue":"5","key":"839_CR106","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(89)90690-9","volume":"56","author":"CL Mendelsohn","year":"1989","unstructured":"Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the Immunoglobulin superfamily. Cell. 1989;56(5):855\u201365.","journal-title":"Cell"},{"issue":"11","key":"839_CR107","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1158\/1078-0432.CCR-19-0483","volume":"25","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Bonecchi R. One Clever macrophage checkpoint. Clin Cancer Research: Official J Am Association Cancer Res. 2019;25(11):3202\u20134.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"839_CR108","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.omtn.2019.09.014","volume":"18","author":"SY Lin","year":"2019","unstructured":"Lin SY, Hu FF, Miao YR, Hu H, Lei Q, Zhang Q, et al. Identification of STAB1 in multiple datasets as a prognostic factor for cytogenetically normal AML: mechanism and drug indications. Mol Therapy Nucleic Acids. 2019;18:476\u201384.","journal-title":"Mol Therapy Nucleic Acids"},{"issue":"1","key":"839_CR109","doi-asserted-by":"publisher","first-page":"16775","DOI":"10.1038\/s41598-025-01675-y","volume":"15","author":"S Aakko","year":"2025","unstructured":"Aakko S, Ylitalo A, Kuusanm\u00e4ki H, Rannikko JH, Bj\u00f6rkman M, Mandelin J, et al. CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to Azacitidine and venetoclax in myeloid malignancies. Sci Rep. 2025;15(1):16775.","journal-title":"Sci Rep"},{"issue":"13","key":"839_CR110","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/cncr.35315","volume":"130","author":"WY Jen","year":"2024","unstructured":"Jen WY, Konopleva M, Pemmaraju N. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer. 2024;130(13):2260\u201371.","journal-title":"Cancer"},{"issue":"3","key":"839_CR111","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","volume":"8","author":"AA Lane","year":"2024","unstructured":"Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, et al. Phase 1b trial of Tagraxofusp in combination with Azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024;8(3):591\u2013602.","journal-title":"Blood Adv"},{"issue":"7","key":"839_CR112","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/2326-6066.CIR-23-0692","volume":"12","author":"M Bianchi","year":"2024","unstructured":"Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Gr\u00fcbler Y, et al. The CD33xCD123xCD70 multispecific CD3-Engaging DARPin MP0533 induces selective T Cell-Mediated killing of AML leukemic stem cells. Cancer Immunol Res. 2024;12(7):921\u201343.","journal-title":"Cancer Immunol Res"},{"key":"839_CR113","doi-asserted-by":"crossref","unstructured":"Collados-Ros A, Muro M, Legaz I. Gemtuzumab Ozogamicin in acute myeloid leukemia: efficacy, toxicity, and resistance Mechanisms-A systematic review. Biomedicines. 2024;12(1).","DOI":"10.3390\/biomedicines12010208"},{"key":"839_CR114","doi-asserted-by":"crossref","unstructured":"Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerov\u00e1 B, \u0160r\u00e1mek J et al. Gemtuzumab Ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis. Leukemia. 2025.","DOI":"10.1038\/s41375-025-02700-9"},{"issue":"1","key":"839_CR115","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1002\/hem3.70060","volume":"9","author":"S Cocciardi","year":"2025","unstructured":"Cocciardi S, Saadati M, Wei\u00df N, Sp\u00e4th D, Kapp-Schwoerer S, Schneider I, et al. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. HemaSphere. 2025;9(1):e70060.","journal-title":"HemaSphere"},{"issue":"7","key":"839_CR116","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","volume":"10","author":"H D\u00f6hner","year":"2023","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, K\u00fchn MWM, Schroeder T, et al. Intensive chemotherapy with or without Gemtuzumab Ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10(7):e495\u2013509.","journal-title":"Lancet Haematol"},{"issue":"8","key":"839_CR117","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41375-022-01622-0","volume":"36","author":"MO Gbadamosi","year":"2022","unstructured":"Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, et al. A ten-gene DNA-damage response pathway gene expression signature predicts Gemtuzumab Ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. Leukemia. 2022;36(8):2022\u201331.","journal-title":"Leukemia"},{"issue":"5","key":"839_CR118","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1111\/bjh.17943","volume":"196","author":"R Dillon","year":"2022","unstructured":"Dillon R, Hills RK, Burnett AK, Russell NH. Gemtuzumab Ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK medical research Council AML15 and AML16 trials. Br J Haematol. 2022;196(5):e50\u20132.","journal-title":"Br J Haematol"},{"issue":"6","key":"839_CR119","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/bjh.19436","volume":"204","author":"C R\u00f6llig","year":"2024","unstructured":"R\u00f6llig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, et al. Gemtuzumab Ozogamicin plus midostaurin in combination with standard \u20187\u2009+\u20093\u2019 induction therapy in newly diagnosed AML: results from the SAL-MODULE phase I study. Br J Haematol. 2024;204(6):2254\u20138.","journal-title":"Br J Haematol"},{"issue":"11","key":"839_CR120","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, et al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with Gemtuzumab Ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022;97(11):1427\u201334.","journal-title":"Am J Hematol"},{"issue":"26","key":"839_CR121","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood.2020005998","volume":"136","author":"S Kapp-Schwoerer","year":"2020","unstructured":"Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Kr\u00f6nke J, et al. Impact of Gemtuzumab Ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09\u201309 trial. Blood. 2020;136(26):3041\u201350.","journal-title":"Blood"},{"issue":"2","key":"839_CR122","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjh.18203","volume":"198","author":"C Dhunputh","year":"2022","unstructured":"Dhunputh C, Strullu M, Petit A, Merched M, Pasquet M, Azarnoush S, et al. Single-dose (4.5\u00a0mg\/m(2)) Gemtuzumab Ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. Br J Haematol. 2022;198(2):373\u201381.","journal-title":"Br J Haematol"},{"issue":"20","key":"839_CR123","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1182\/blood.2023020630","volume":"142","author":"SD Freeman","year":"2023","unstructured":"Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, et al. Fractionated vs single-dose Gemtuzumab Ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. Blood. 2023;142(20):1697\u2013707.","journal-title":"Blood"},{"key":"839_CR124","doi-asserted-by":"crossref","unstructured":"Martinez Flores D, Akhoundova D, Seipel K, Legros M, Kronig MN, Daskalakis M et al. Gemtuzumab Ozogamicin and stem cell mobilization for autologous stem cell transplantation in favorable risk acute myeloid leukemia. Biomedicines. 2024;12(7).","DOI":"10.3390\/biomedicines12071616"},{"issue":"3","key":"839_CR125","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25(3):388\u201399.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"839_CR126","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1182\/blood-2023-187642","volume":"142","author":"D Dutta","year":"2023","unstructured":"Dutta D, Pan P, Fleming R, Andrade-Campos M, Belova E, Wheeler J, et al. First disclosure of AZD9829, a TOP1i-ADC targeting CD123: promising preclinical activity in AML models with minimal effect on healthy progenitors. Blood. 2023;142(Supplement 1):5957.","journal-title":"Blood"},{"issue":"6","key":"839_CR127","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/cncr.32657","volume":"126","author":"R Narayan","year":"2020","unstructured":"Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, et al. A phase 1 study of the antibody-drug conjugate Brentuximab Vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed\/refractory acute myeloid leukemia. Cancer. 2020;126(6):1264\u201373.","journal-title":"Cancer"},{"key":"839_CR128","doi-asserted-by":"crossref","unstructured":"Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A et al. Nivolumab plus 5-Azacitidine in pediatric relapsed\/refractory acute myeloid leukemia (AML): phase I\/II trial results from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Cancers. 2024;16(3).","DOI":"10.3390\/cancers16030496"},{"issue":"1","key":"839_CR129","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 Blockade therapy. Nat Commun. 2021;12(1):6071.","journal-title":"Nat Commun"},{"issue":"15","key":"839_CR130","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/bloodadvances.2024015200","volume":"9","author":"JM Magenau","year":"2025","unstructured":"Magenau JM, Frame DG, Riwes M, Maciejewski J, Anand S, Pawarode A, et al. PD-1 Inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2025;9(15):3878\u201386.","journal-title":"Blood Adv"},{"issue":"2","key":"839_CR131","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143\u201353.","journal-title":"N Engl J Med"},{"key":"839_CR132","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Westermann J, Kovacsovics T, Assouline S, Schuh AC, Kim HJ, et al. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML). Clinical Lymphoma Myeloma and Leukemia. 2022;22:S255.","DOI":"10.1016\/S2152-2650(22)01303-9"},{"issue":"18","key":"839_CR133","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","volume":"81","author":"LC Tsao","year":"2021","unstructured":"Tsao LC, Force J, Hartman ZC. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 2021;81(18):4641\u201351.","journal-title":"Cancer Res"},{"issue":"31","key":"839_CR134","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody Magrolimab combined with Azacitidine in patients with previously untreated AML: phase Ib results. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(31):4893\u2013904.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"4","key":"839_CR135","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","volume":"208","author":"A Anzueto","year":"2023","unstructured":"Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, Double-Blind, Placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med. 2023;208(4):406\u201316.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"839_CR136","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and Azacitidine plus Magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146(5):601\u201311.","journal-title":"Blood"},{"issue":"9","key":"839_CR137","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26(9):1459\u201367.","journal-title":"Nat Med"},{"key":"839_CR138","doi-asserted-by":"crossref","unstructured":"Walter RB. Where do we stand with radioimmunotherapy for acute myeloid leukemia? Expert opinion on biological therapy. 2022;22(5):555\u201361.","DOI":"10.1080\/14712598.2022.2060735"},{"issue":"2","key":"839_CR139","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-23-1200","volume":"30","author":"JJ Orozco","year":"2024","unstructured":"Orozco JJ, Vo PT, Gooley TA, Haaf RL, Lundberg SJ, Hamlin DK, et al. Targeted radiation delivery before haploidentical HCT for High-risk leukemia or MDS patients yields Long-term survivors. Clin Cancer Research: Official J Am Association Cancer Res. 2024;30(2):274\u201382.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"839_CR140","doi-asserted-by":"crossref","unstructured":"Tomlinson BK, Reddy V, Berger MS, Spross J, Lichtenstein R, Gyurkocza B. Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial. 2019;37(15_suppl):7048.","DOI":"10.1200\/JCO.2019.37.15_suppl.7048"},{"issue":"12","key":"839_CR141","doi-asserted-by":"publisher","first-page":"101307","DOI":"10.1016\/j.xcrm.2023.101307","volume":"4","author":"JH Rannikko","year":"2023","unstructured":"Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, et al. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I\/II first-in-human MATINS trial. Cell Rep Med. 2023;4(12):101307.","journal-title":"Cell Rep Med"},{"key":"839_CR142","doi-asserted-by":"crossref","unstructured":"Allen C, Zeidan AM, Bewersdorf JP, BiTEs. DARTS, bikes and TriKEs-Are antibody based therapies changing the future treatment of AML? Life (Basel. Switzerland). 2021;11(6).","DOI":"10.3390\/life11060465"},{"key":"839_CR143","doi-asserted-by":"crossref","unstructured":"Tabata R, Chi S, Yuda J, Minami Y. Emerging immunotherapy for acute myeloid leukemia. Int J Mol Sci. 2021;22(4).","DOI":"10.3390\/ijms22041944"},{"issue":"6","key":"839_CR144","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2217\/fon.12.54","volume":"8","author":"F McAleese","year":"2012","unstructured":"McAleese F, Eser M. RECRUIT-TandAbs: Harnessing the immune system to kill cancer cells. Future Oncol (London England). 2012;8(6):687\u201395.","journal-title":"Future Oncol (London England)"},{"issue":"2","key":"839_CR145","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4161\/mabs.27385","volume":"6","author":"DL Rossi","year":"2014","unstructured":"Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. mAbs. 2014;6(2):381\u201391.","journal-title":"mAbs"},{"issue":"35","key":"839_CR146","doi-asserted-by":"publisher","first-page":"14706","DOI":"10.1074\/jbc.M117.793497","volume":"292","author":"C De Nardis","year":"2017","unstructured":"De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, et al. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human Immunoglobulin G(1). J Biol Chem. 2017;292(35):14706\u201317.","journal-title":"J Biol Chem"},{"key":"839_CR147","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ymeth.2018.10.006","volume":"154","author":"GL Moore","year":"2019","unstructured":"Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen DT, Jacinto J, et al. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods (San Diego Calif). 2019;154:38\u201350.","journal-title":"Methods (San Diego Calif)"},{"issue":"3","key":"839_CR148","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, B\u00f6geholz J, K\u00f6hnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123(3):356\u201365.","journal-title":"Blood"},{"issue":"6","key":"839_CR149","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","volume":"13","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, et al. Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13(6):1549\u201357.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"839_CR150","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","volume":"6","author":"R Jitschin","year":"2018","unstructured":"Jitschin R, Saul D, Braun M, Tohumeken S, V\u00f6lkl S, Kischel R, et al. CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer. 2018;6(1):116.","journal-title":"J Immunother Cancer"},{"key":"839_CR151","doi-asserted-by":"crossref","unstructured":"Ravandi F, Walter RB, Subklewe M, Buecklein VL, Jongen-Lavrencic M, Paschka P et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). 2020;38:7508-.","DOI":"10.1200\/JCO.2020.38.15_suppl.7508"},{"issue":"23","key":"839_CR152","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-16-0350","volume":"22","author":"U Reusch","year":"2016","unstructured":"Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, et al. Characterization of CD33\/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Research: Official J Am Association Cancer Res. 2016;22(23):5829\u201338.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"Supplement1","key":"839_CR153","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood-2019-129042","volume":"134","author":"P Westervelt","year":"2019","unstructured":"Westervelt P, Cortes JE, Altman JK, Long M, Oehler VG, Gojo I, et al. Phase 1 First-in-Human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-Cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2019;134(Supplement1):834.","journal-title":"Blood"},{"key":"839_CR154","doi-asserted-by":"crossref","unstructured":"Starodub A, Piha-Paul SA, Karim R, Ruegg C, Smith V, Chun PY. A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors. 2020;38(15_suppl):3101-.","DOI":"10.1200\/JCO.2020.38.15_suppl.3101"},{"issue":"7","key":"839_CR155","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","volume":"19","author":"PF van Loo","year":"2019","unstructured":"van Loo PF, Hangalapura BN, Thordardottir S, Gibbins JD, Veninga H, Hendriks LJA, et al. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast Lysis. Expert Opin Biol Ther. 2019;19(7):721\u201333.","journal-title":"Expert Opin Biol Ther"},{"key":"839_CR156","unstructured":"Mascarenhas JCJ, Huls G, Venditti A, Breems D, De Botton S et al. Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients (pts) with acute myelogenous leukemia (AML). Eur Hematol Association. 2020;EP538."},{"key":"839_CR157","doi-asserted-by":"crossref","unstructured":"Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A et al. A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancers. 2021;13(16).","DOI":"10.3390\/cancers13164113"},{"key":"839_CR158","doi-asserted-by":"crossref","unstructured":"Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ et al. Risk, characteristics and biomarkers of cytokine release syndrome in patients with relapsed\/refractory AML or MDS treated with CD3xCD123 bispecific antibody APVO436. 2021;13(21):5287.","DOI":"10.3390\/cancers13215287"},{"issue":"5","key":"839_CR159","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/bloodadvances.2019001188","volume":"4","author":"P Nair-Gupta","year":"2020","unstructured":"Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K, et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell Redirection activity against acute myeloid leukemia. Blood Adv. 2020;4(5):906\u201319.","journal-title":"Blood Adv"},{"issue":"3","key":"839_CR160","doi-asserted-by":"publisher","first-page":"e13742","DOI":"10.1111\/cts.13742","volume":"17","author":"R Narayan","year":"2024","unstructured":"Narayan R, Pi\u00e9rola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, et al. First-in-human study of JNJ-67571244, a CD33 \u00d7 CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome. Clin Transl Sci. 2024;17(3):e13742.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"839_CR161","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","volume":"399","author":"S Johnson","year":"2010","unstructured":"Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010;399(3):436\u201349.","journal-title":"J Mol Biol"},{"issue":"289","key":"839_CR162","doi-asserted-by":"publisher","first-page":"289ra82","DOI":"10.1126\/scitranslmed.aaa5693","volume":"7","author":"GR Chichili","year":"2015","unstructured":"Chichili GR, Huang L, Li H, Burke S, He L, Tang Q, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):289ra82.","journal-title":"Sci Transl Med"},{"issue":"1","key":"839_CR163","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","volume":"127","author":"M Al-Hussaini","year":"2016","unstructured":"Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127(1):122\u201331.","journal-title":"Blood"},{"issue":"6","key":"839_CR164","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751\u201362.","journal-title":"Blood"},{"issue":"14","key":"839_CR165","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33\u2009+\u2009Targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Research: Official J Am Association Cancer Res. 2016;22(14):3440\u201350.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"Supplement 1","key":"839_CR166","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/blood-2018-99-117150","volume":"132","author":"US Arvindam","year":"2018","unstructured":"Arvindam US, van Hauten P, Hallstrom C, Vallera DA, Dolstra H, Miller JS, et al. CD16-IL15-CLEC12A trispecific killer engager (TriKE) drives NK cell expansion, activation, and antigen specific killing of cancer stem cells in acute myeloid leukemia. Blood. 2018;132(Supplement 1):1454.","journal-title":"Blood"},{"issue":"12","key":"839_CR167","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.ymthe.2021.06.018","volume":"29","author":"E Chiu","year":"2021","unstructured":"Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K, et al. Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C(+) NK cells to target myeloid leukemia. Mol Therapy: J Am Soc Gene Therapy. 2021;29(12):3410\u201321.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"4","key":"839_CR168","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"839_CR169","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"key":"839_CR170","doi-asserted-by":"publisher","first-page":"1145441","DOI":"10.3389\/fimmu.2023.1145441","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, et al. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol. 2023;14:1145441.","journal-title":"Front Immunol"},{"issue":"9","key":"839_CR171","doi-asserted-by":"publisher","first-page":"e1043","DOI":"10.1002\/ctm2.1043","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang L, Huang H, Tang Y, Li Q, Wang J, Li D, et al. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clin Translational Med. 2022;12(9):e1043.","journal-title":"Clin Translational Med"},{"issue":"1","key":"839_CR172","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):82.","journal-title":"J Hematol Oncol"},{"key":"839_CR173","doi-asserted-by":"crossref","unstructured":"Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized Rapamycin dosing. J Clin Investig. 2024;134(9).","DOI":"10.1172\/JCI162593"},{"issue":"1","key":"839_CR174","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","volume":"18","author":"J Yin","year":"2025","unstructured":"Yin J, Cui QY, Dai HP, Qu CJ, Li Z, Kang LQ, et al. CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial. J Hematol Oncol. 2025;18(1):53.","journal-title":"J Hematol Oncol"},{"key":"839_CR175","doi-asserted-by":"crossref","unstructured":"Sallman DA. Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T\u00ae Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients. Blood. 2022;140.","DOI":"10.1182\/blood-2022-169142"},{"issue":"12","key":"839_CR176","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024;30(12):3697\u2013708.","journal-title":"Nat Med"},{"issue":"8000","key":"839_CR177","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"11","key":"839_CR178","first-page":"5559","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Meng Y, Yao H, Zhan R, Chen S, Miao W, et al. CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future. Am J Cancer Res. 2023;13(11):5559\u201376.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"839_CR179","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15(1):8439.","journal-title":"Nat Commun"},{"issue":"9","key":"839_CR180","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41587-022-01626-2","volume":"41","author":"L Gauthier","year":"2023","unstructured":"Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, et al. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123. Nat Biotechnol. 2023;41(9):1296\u2013306.","journal-title":"Nat Biotechnol"},{"key":"839_CR181","doi-asserted-by":"crossref","unstructured":"Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G et al. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European journal of cancer (Oxford, England: 1990). 2022;160:112\u2009\u2013\u200933.","DOI":"10.1016\/j.ejca.2021.10.016"},{"issue":"1","key":"839_CR182","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40164-025-00686-9","volume":"14","author":"R Cai","year":"2025","unstructured":"Cai R, Lu B, Zhao X, Zhou S, Li Y. iPSC-derived NK cells engineered with CD226 effectively control acute myeloid leukemia. Experimental Hematol Oncol. 2025;14(1):93.","journal-title":"Experimental Hematol Oncol"},{"issue":"1","key":"839_CR183","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1475-2867-13-13","volume":"13","author":"C Lin","year":"2013","unstructured":"Lin C, Li Y. The role of peptide and DNA vaccines in myeloid leukemia immunotherapy. Cancer Cell Int. 2013;13(1):13.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"839_CR184","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ajh.24014","volume":"90","author":"J Brayer","year":"2015","unstructured":"Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, et al. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015;90(7):602\u20137.","journal-title":"Am J Hematol"},{"issue":"10","key":"839_CR185","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1586\/erv.09.90","volume":"8","author":"M Schmitt","year":"2009","unstructured":"Schmitt M, Casalegno-Gardu\u00f1o R, Xu X, Schmitt A. Peptide vaccines for patients with acute myeloid leukemia. Expert Rev Vaccines. 2009;8(10):1415\u201325.","journal-title":"Expert Rev Vaccines"},{"key":"839_CR186","doi-asserted-by":"publisher","first-page":"1458449","DOI":"10.3389\/fonc.2024.1458449","volume":"14","author":"S Jung","year":"2024","unstructured":"Jung S, Nelde A, Maringer Y, Denk M, Zieschang L, Kammer C, et al. AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients. Front Oncol. 2024;14:1458449.","journal-title":"Front Oncol"},{"key":"839_CR187","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2015.00036","volume":"6","author":"A Di Stasi","year":"2015","unstructured":"Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol. 2015;6:36.","journal-title":"Front Immunol"},{"issue":"18","key":"839_CR188","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985\u201394.","journal-title":"Blood"},{"issue":"26","key":"839_CR189","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and Immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541\u20138.","journal-title":"Blood"},{"issue":"3","key":"839_CR190","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224\u201334.","journal-title":"Blood Adv"},{"issue":"6","key":"839_CR191","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543784.2021.1928635","volume":"30","author":"AG Jain","year":"2021","unstructured":"Jain AG, Talati C, Pinilla-Ibarz J. Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2021;30(6):595\u2013601.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"839_CR192","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265\u2013e8124.","journal-title":"Cell"},{"key":"839_CR193","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cytogfr.2025.04.002","volume":"83","author":"A Wu","year":"2025","unstructured":"Wu A, Zhang T, Yu H, Cao Y, Zhang R, Shao R, et al. Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement. Cytokine Growth Factor Rev. 2025;83:66\u201376.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7949","key":"839_CR194","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348.","journal-title":"Nature"},{"issue":"4","key":"839_CR195","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabol. 2022;34(4):595\u2013e61414.","journal-title":"Cell Metabol"},{"issue":"7952","key":"839_CR196","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507\u201316.","journal-title":"Nature"},{"issue":"3","key":"839_CR197","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-Gated ROR1 chimeric antigen receptor expression rescues T Cell-Mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35(3):489\u2013e5038.","journal-title":"Cancer Cell"},{"issue":"7","key":"839_CR198","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the Art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"key":"839_CR199","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-Engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13:835762.","journal-title":"Front Immunol"},{"issue":"1","key":"839_CR200","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","volume":"22","author":"EA Golikova","year":"2024","unstructured":"Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J Translational Med. 2024;22(1):897.","journal-title":"J Translational Med"},{"issue":"1","key":"839_CR201","doi-asserted-by":"publisher","first-page":"11894","DOI":"10.1038\/s41598-025-92209-z","volume":"15","author":"F Zhao","year":"2025","unstructured":"Zhao F, Zhang X, Tang Y, Yang H, Pan H, Li B, et al. Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells. Sci Rep. 2025;15(1):11894.","journal-title":"Sci Rep"},{"issue":"2","key":"839_CR202","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41375-021-01375-2","volume":"36","author":"Y Xu","year":"2022","unstructured":"Xu Y, Mou J, Wang Y, Zhou W, Rao Q, Xing H, et al. Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway. Leukemia. 2022;36(2):403\u201315.","journal-title":"Leukemia"},{"issue":"12","key":"839_CR203","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1182\/blood-2002-04-1063","volume":"100","author":"BJ Weigel","year":"2002","unstructured":"Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, et al. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF\/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood. 2002;100(12):4169\u201376.","journal-title":"Blood"},{"key":"839_CR204","doi-asserted-by":"crossref","unstructured":"Yin J, Luo J, Wang L, Liu L, Liu L. STAB1 promotes acute myeloid leukemia progression by activating the IKK\/NF-\u03baB pathway and increasing M2 macrophage polarization. Cancer Sci. 2025.","DOI":"10.1111\/cas.70044"},{"key":"839_CR205","doi-asserted-by":"publisher","first-page":"977358","DOI":"10.3389\/fimmu.2022.977358","volume":"13","author":"M Gimeno","year":"2022","unstructured":"Gimeno M, San Jos\u00e9-En\u00e9riz E, Villar S, Agirre X, Prosper F, Rubio A, et al. Explainable artificial intelligence for precision medicine in acute myeloid leukemia. Front Immunol. 2022;13:977358.","journal-title":"Front Immunol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00839-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:34:19Z","timestamp":1760456059000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":205,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00839-2","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}